Skip to main content

Table 1 Demographic and clinical data

From: Predictors for good functional outcome after neurocritical care

 

All

Ischemia

ICH

SAH

Meningoencephalitis

Epilepsy

GBS/MG

Neurodeg/Encephalopathy

Neoplasm

Intoxication

Temporarily monitored

n (%)

733

247 (33.7)

210 (27.4)

38 (5.2)

49 (6.7)

93 (12.7)

25 (3.4)

22 (3.0)

22 (3.0)

27 (3.7)

63

Age (median, range)

67 (18 to 95)

72 (21 to 93)

70 (35 to 95)

56 (19 to 84)

63 (27 to 85)

59 (18 to 93)

58 (23 to 78)

66 (23 to 90)

65 (39 to 78)

53 (29 to 78)

51 (33 to 68)

Female sex (n, %)

350 (47.7)

111 (44.9 )

100 (47.6)

20 (52.6)

26 (53.1)

48 (51.6)

14 (56)

14 (63.6)

8 (36.4)

9 (33.3)

26 (41.3)

Pre-hospital mRS 0 to 2 n (%)

635 (86.6)

227 (91.9)

198 (94.3)

37 (97.4)

43 (87.8)

71 (76.3)

24 (96.0)

8 (36.4)

4 (18.2)

23 (85.2)

47 (74.6)

Hospital length of stay in days (median, range)

4 (0 to 87)

4 (0 to 57)

5 (0 to 53)

4 (0 to 63)

4 (0 to 84)

1 (0 to 87)

6 (0 to 57)

3 (1 to 50)

3 (0 to 17)

3 (0 to 19)

1 (0 to 2)

Mechanichal ventilation (n, %)

450 (61.4)

148 (59.9)

140 (66.7)

20 (52.6)

42 (85.7)

48 (51.6)

16 (64.0)

18 (81.8)

8 (36.4)

20 (74.1)

18 (28.6)

Length of ventilation (d) (median, range)

3 (0 to 83)

4 (0 to 43)

5 (0 to 53)

1(0 to 60)

4 (0 to 83)

0 (0 to 63)

6 (0 to 49)

3 (0 to 50)

0 (0 to 13)

3 (0 to 14)

0 (0 to 1)

DNT (n, %)

38 (5.1)

9 (3.6)

22 (10.5)

3 (7.9)

0

0

0

2 (9.1)

2 (9.1)

0

0

Lost to follow-up (n, %)

29 (4.0)

6 (2.4)

5 (2.4)

1 (2.6)

2 (4.1)

7 (7.5)

1 (4)

2 (9.1)

3 (13.6)

2 (7.4)

16 (25.4)

In-hospital mortality (n, %)

165 (22.5)

53 (21.5)

75 (35.7)

12 (31.6)

3 (6.1)

5 (5.4)

1 (4.0)

4 (18.2)

7 (31.8)

5 (18.5)

0

Mortality after 1 year (n, %)

292 (39.8)

100 (41.5)

121 (59.0)

18 (48.6)

6 (12.8)

14 (16.3)

1 (4.2)

11 (55.0)

15 (78.9)

6 (24.6)

1 (2.1)

mRS 0 to 2 after 1 year (n, %)

208 (28.4)

33 (13.7)

40 (19.5)

11 (29.7)

28 (59.6)

57 (66.3)

16 (66.7)

5 (25.0)

1 (5.3)

17 (68.0)

38 (80.9)

  1. Demographic and clinical characteristics of all patients (n = 796) including a separate analysis for admission diagnosis (intention-to-treat cohort).
  2. Patients who were excluded for the per protocol-analysis are highlighted in bold. (PS: All patients monitored only temporarily (right column) are not included in the overall numbers (left column). Patients lost to follow up are not included in mortality and functional outcome after one year.)
  3. Abbreviations: ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; Neurodeg, neurodegenerative disease; n, number; d, days.